Advertisement


Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

2016 ASCO Annual Meeting

Advertisement

Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).



Related Videos

Pancreatic Cancer

John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial

John P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecitabine vs monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Abstract LBA4006).

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

To see Dr. Paz-Ares discuss this video in Spanish, please click here.

Global Cancer Care

Rakesh Chopra, MD, and Mary Gospodarowicz, MD, on The Indian Perspective of the Current State of Cancer Research and Treatment

Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.

Cost of Care
Issues in Oncology

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.

Kidney Cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).

Advertisement

Advertisement



Advertisement